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Kawasaki disease (KD) is an acute inflammatory vasculitis occurring in young children
before 5 years and representing at this age, the main cause of acquired heart disease.
A single infusion of 2 g/kg of intravenous immunoglobulins along with aspirin has
reduced the frequency of coronary artery aneurysms from 25 to 5%. However, 10–20%
of patients do not respond to standard treatment and have an increased risk of cardiac
complications and death. The development of more potent therapeutic approaches of
KD is an urgent need. Phenotypical and immunological similarities between KD and
systemic juvenile idiopathic arthritis led to the hypothesis that KD could be considered as
an autoinflammatory disease. New insights regarding KD’s pathogenesis have merged
from the combination of genetic and transcriptomic data revealing the key role of
interleukin-1 (IL-1) signaling in the pathogenesis of the vasculitis. Once activated, IL-
1α and IL-1β trigger a local proinflammatory environment-inducing vasodilatation and
attracting monocytes and neutrophils to sites causing tissue damage and stress. Both
IL-1α and IL-1β have been shown to induce myocarditis and aneurysm formation
in Lactobacillus casei cell-wall extract mouse model of KD; both being successfully
improved with IL-1 blockade treatment such as anakinra. Treatment failure in patients
with the high-risk inositol-triphosphate 3-kinase C genotype was associated with highest
basal and stimulated intracellular calcium levels, increased cellular production of IL-1β,
and IL-18, and higher circulating levels of both cytokines. Three clinical trials of IL-1
blockade enrolling KD patients are currently being conducted in Western Europe and in
USA, they could change KD outcome.
Keywords: Kawasaki disease, vasculitis, pediatric, interleukin-1, coronary artery aneurysms, pediatrics,
autoinflammatory disease
INTRODUCTION
Kawasaki disease (KD) is an acute inflammatory vasculitis of the medium- and small-sized
arteries generally occurring in children under 5 years old. It was first described by Kawasaki,
1967 associated with the development of coronary artery aneurysms (CAA) or ecstasies in
15–25% of untreated children. Coronary lesions may lead to ischemic heart disease and
sudden death. The etiopathology of KD remains unknown though it is widely accepted
that it results in an important inflammation cascade triggered by unknown infectious or
other stress trigger in a genetically predisposed individual. A single infusion of 2 g/kg
of intravenous immunoglobulins (IVIGs) along with aspirin is the standard treatment for
KD but not all children may respond, especially the youngest ones and those predisposed
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to develop CAA. Interleukin 1 (IL-1) cytokine has been shown to
play a key role in the development of CAA leading to a potential
use of IL-1 blockade in patients with KD.
KAWASAKI DISEASE
Classically, KD is diagnosed in the presence of high fever lasting
for at least 5 days associated to at least four principal features
(Table 1). No blood tests are available for diagnosis of KD,
therefore, a clinical algorithm has been established and validated
by the American Academy of pediatrics (Table 1) (Newburger
et al., 2004). In some cases, KD diagnosis can be made at day 4 of
illness in the presence of ≥4 principal criteria. Some patients have
incomplete KD, especially infants ≤6 months. In this situation,
KD diagnosis is challenging and should be looked for in infants
with ≥7 days of fever without explanations, even though no KD
clinical criteria are found. In this case, children should, therefore,
undergo laboratory testing and, if any systemic inflammation
is found, an echocardiogram should be performed (Newburger
et al., 2004). Echocardiographic evaluation should be performed
at the time of diagnosis, at 2 weeks and at 6–8 weeks after
onset of the disease. More frequent echocardiographic evaluation
is needed in children at higher risk (Newburger et al., 2004).
Kawasaki disease vasculitis may occur outside the heart in other
medium-sized vessel such as axillary, renal and femoral arteries
somewhat difficult to distinguish from infantile periarteritis
nodosa (Burns and Glodé, 2004).
Treatment in KD
A single infusion of 2 g/kg of IVIG along with aspirin has reduced
CAA frequency from 25 to 5%. However, 10–20% of patients do
not respond to standard treatment and have an increased risk of
cardiac complications and death.
Corticosteroids (CS) as well as anti-tumor necrosis factor
(TNF) agents are the two main treatments used in IVIG-resistant
patients (Eleftheriou et al., 2014). Although there are no formal
recommendations regarding optimal CS doses and duration
(Chen et al., 2013), CS has not shown significant differences
compared to an additional IVIG treatment in terms of preventing
the development of CAA (Miura et al., 2008; Ogata et al., 2009).
The elevated level of TNF-α in the sera of KD patients correlated
with CAA development has led to the use of anti-TNF agent
(Eleftheriou et al., 2014). The most frequently used is infliximab
(IFX), a chimeric murine/human IgG1 monoclonal antibody
that binds to TNF-α. This treatment has been administered
in IVIG-resistant patients with success regarding fever and
inflammatory parameters, however, with no differences regarding
cardiac disease (Burns et al., 2005, 2008; Son et al., 2011). Other
immunosuppressive agents have occasionally been used such
as: cyclosporine, cyclophosphamide, methotrexate, and plasma
exchange in resistant KD patients to IVIG, steroids, and anti-
TNFα (Galeotti et al., 2016).
Although the use of different treatments has changed KD
outcome, this disease is still lethal in certain cases. The
individual prognostic factors are still poorly defined, and
resistance to standard therapy represents a major risk of
cardiac complications. Developing more efficient treatments
and with a better action on cardiac involvement seems a
priority. The phenotypical similarities between KD and systemic
autoinflammatory disease (SAID) led researches to look at the
role of inflammatory cytokines namely IL-1 in KD.
Why to Use IL-1 Blockade in KD?
KD and Systemic Juvenile Idiopathic Arthritis (SJIA):
Is There a Missing Link?
Kawasaki disease and SJIA represent a major cause of fever
of unknown origin in young children and share intriguing
TABLE 1 | Kawasaki disease (KD) clinical algorithm (Newburger et al., 2004).
Typical KD Positive echocardiogram (1/3 conditions)
Fever persisting at least 5 days associated to at least four of the five principal features LAD or RCA ≥ 2.5 Z-score
Changes in the peripheral extremities: Any coronary segment with an internal lumen diameter Z-score ≥ 2.5
– Palm and soles erythema
– Feet and hand edema
– Peeling of the hands and feet at week 2 or 3
Bilateral non-exudative conjunctivitis 3/6 features • Perivascular brightness
Changes in the oral cavity: • Lack of taperin
– Lips dryness • Decreased LV function
– Erythema • Mitral regurgitation
– Strawberry tongue • Pericardial effusion
– Diffuse injection of mouth and throat mucosa • LAD or RCA: 2–2.5 Z-score
Cervical lymphadenopathy >1.5 cm diameter and usually unilateral Supplementary laboratory criteria
Polymorphous exanthema • Albumin ≤3 g/dl
• Anemia for age
• Elevation of alanine aminotransferase
• Platelets 450,000/mm3 after 7 days of fever
• White blood cell count ≥15000/mm3
• Urine white blood cells >10 cells per high-power field
Proximal right coronary artery (RCA) or left anterior descending coronary artery (LAD).
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similarities. Clinically, both diseases present with high fever,
macular rashes, myalgia, arthralgia, and adenopathy although
arthritis seems to be specific to SJIA (Lefèvre-Utile et al.,
2014); for this reason, it is difficult to differentiate KD from
early SJIA especially when KD is incomplete. Early age of
presentation seems to favor KD. Moreover, cardiac abnormalities
have been described, especially serositis as in many SAID.
Unlike KD, SJIA coronary lesions are mild (essentially hyper
echogenic coronaries) with favorable evolution; no CAA are
described. Because of CAA risk in incomplete KD and need
for early treatment, many patients with SJIA may be initially
treated as KD, with IVIG and aspirin, but without efficacy
(Lefèvre-Utile et al., 2014). Looking at laboratory findings, no
differences can be seen. Both present elevated C-reactive protein,
leukocytosis, thrombocytosis, hypoalbuminemia, anemia, and
even macrophage activation syndrome (MAS) (Lefèvre-Utile
et al., 2014). Assumptions have been made that these two systemic
inflammatory disorders could share common triggering agents,
susceptibility factors, or immunopathogenic pathways.
When looking at sera of KD and SJIA patients, inflammatory
cytokines such as IL-1, IL-6, TNF-α, and interleukin-18 (IL-18)
are increased. IL-18 being specifically higher in SJIA compared to
KD patient (Mizuta et al., 2016). These phenotypical similarities
between KD and SJIA along with the immunological features led
to the hypothesis that KD could be considered as an SAID as SJIA
and cryopyrin-associated periodic syndrome (CAPS) (Alphonse
et al., 2016).
IL-1 Signature in SJIA and KD:
Inflammatory cytokines, especially IL-1β, has first been described
as markedly increased in SAID such as CAPS and SJIA
(Goldbach-Mansky, 2012). CAPS has allowed to understand
the key role of IL-1 in the disease pathogenesis and showed
striking response to IL-1-blocking therapies (Ter Haar et al.,
2013). NLRP3 is a nod-like receptor (NLR) that is part of
an inflammasome, which activates the caspase-1 (CASP1) and
consequently the secretion of active IL-1β and IL-18 (Baroja-
Mazo et al., 2014). NLRP3 gene mutations result in constitutive
activation of the NLRP3 protein and in an amplification loop of
inflammation in which normal regulatory systems, i.e., ATP and
second signal requirement are debrided, and where the pro IL-1β
may act itself as a danger signal (Koné-Paut and Galeotti, 2015).
More recently, IL-1 has been shown to play a critical role in
the pathogenesis of SJIA. Pascual et al. (2005) showed three major
results. First, serum from SJIA patients induces the transcription
of innate immunity genes including IL-1 in peripheral blood
mononuclear cells (PBMCs) from healthy volunteers. Second,
when activating PBMCs of SJIA patients, a large amount of IL-
1β is released. Finally, they showed that, the use of recombinant
IL-1 receptor antagonist (IL1-RA) (anakinra) allowed complete
clinical remission in seven of the nine refractory-treated patients
thus, emphasizing the central role of the innate immune system
(IIS), and specifically, inflammasome-derived cytokines, in the
pathogenesis of SJIA (Pascual et al., 2005).
As in systemic diseases, IL-1 seems to play a key role in
the physiopathology of KD and more importantly in cardiac
involvement for various reasons. Alphonse et al. (2016) showed a
significant increased level of IL-1β, IL-18 and of their antagonists
(IL-1RA and IL-18BP) in acute KD patients compared with
age-matched control patients with viral or bacterial infections.
Moreover, IL-1-induced inflammation has been shown to play
a role in acute myocardial infarction and contributes to
acute ischemic diseases. Indeed, IL-1 is known to enhance
the expansion, differentiation and migration of antigen-specific
CD8+ T cells as well as the induction of matrix enzymes source
of major tissue damage. In the heart and brain, this inflammation
can be fatal (Martinon and Tschopp, 2004). In KD, antigen-driven
CD8+ T cells are known to infiltrate the coronary artery wall
and contribute to the pathogenesis of CAA (Brown et al., 2001).
The assumption appears all the more justified when looking at
IVIG mechanism on inflammatory cytokines. In responsive KD
patients treated with IVIG therapy, the level of pro-inflammatory
cytokines (IL-1β, IL-6, and TNF-α) are decreased emphasizing
immunoglobulin’s (IG) effect on the modulation of inflammatory
cytokines namely on IL-1. Although the way IVIG acts is not
perfectly understood, it is known to reduce CAA prevalence
(Galeotti et al., 2010).
Interleukin-1 polymorphisms could be associated either to
response or resistance to IVIG treatment (Weng et al., 2010).
Interestingly elevated transcripts have been shown in IVIG-
resistant KD patients, which carry the highest risk for coronary
aneurysms (Fury et al., 2010). Increased transcript abundance
of the neutrophil-associated calcium-binding proteins, S100A8
and A9, confirms the role of activated neutrophils in acute
KD, as these proteins regulate adhesion of neutrophils and
monocytes to the endothelial cell, a critical process in KD
vasculitis. S100A8/9 proteins are elevated in patients who develop
coronary aneurysms. The S100A8/9 heterodimer is known to
activate the IL-1 receptor-associated kinase and the NF-κB.
S100A8/9 appears to be useful biomarkers for identifying IVIG-
resistant patients. Other markers of endothelial cell activation
CEACCAM1 (carcino embryonic antigen-related cell adhesion)
and VEGF (vascular endothelial growth factor) have been
detected in acute KD and may correlate with IGIV resistance and
coronary vasculitis (Weng et al., 2010).
The role of IIS in the histopathology of KD has also been
shown in vivo in mice.
Mouse Model of CAA- and IL-1-signaling
Pathways
A mouse model of coronary arteritis has been developed using
intraperitoneal injection of Lactobacillus casei cell-wall extract
(LCCWE). This mouse develops a focal, localized coronary
arteritis that histopathologically mimics the coronary artery
lesions found in human KD (Lehman et al., 1985). As in human
CAA, the coronary lesions of LCCWE contains macrophages,
activated dendritic cells, and T cells (Schulte et al., 2009).
Moreover, the CAA in LCCWE mice responds to IVIG therapy
as in KD children (Lehman, 1993). Although both innate
and adaptive immunity have been shown as essential for the
development of CAA in the LCCWE mouse model, IIS seems to
play a key role. Two cytokines have been described as important
in the development of CAA: NF-κB and IL-1. Rosenkranz et al.
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(2005) have pointed out the role of toll-like receptors (TLRs),
a major sensor of IIS, in KD inflammation and therefore in
CAA. In LCCWE, NF- NF-κB, an inflammatory cytokine, is
activated and synthesized after activation of TLR-2 using a
MyD88-dependent pathway (Rosenkranz et al., 2005). NF-κB
activation coordinately controls both the innate and adaptive
immune responses. To induce vasculitis in LCCWE mice, TLR2
are required as IL-1R signaling highlighting, amongst others, the
importance of IL-1-signaling pathway in vasculitis (Rosenkranz
et al., 2005). Both IL-1α and IL-1β have been shown to induce
aneurysm formation in LCCWE mouse model of KD; aneurysm
that are successfully improved with IL-1 blocker treatment
such as anakinra (Schett et al., 2016). Similar successful results
were reported in recalcitrant KD children using IL-1 blockade
(Alphonse et al., 2016).
Lee et al. (2012) presented a mouse model of a knock-out
LCCWE mouse (CASP1-/- and IL-1R-/-) in whom KD finally
developed after injection of recombinant IL1-β protein. This
mouse developed coronary arteritis, which could be prevented
by injection of the IL-1 receptor antagonist (IL-1RA): anakinra,
during 3–5 days. Using the LCWE mouse model, a logical
progression of experiments demonstrated that (i) bone marrow-
derived macrophages secrete high levels of IL-1β and TNFα; (ii)
IL-1β is processed from pro-IL-1β by CASP1 through the NLRP3
inflammasome; (iii) exogenous treatment with IL-1β recreates the
inflammatory phenotype in CASP1 deficient mice; and (iv) IL-
1R-deficient mice or mice treated with the recombinant IL-1RA,
anakinra fail to develop the arteritis lesions. Of particular note,
only blockade of IL-1β, but not blockade of TNF-α, reduced the
myocarditis in the LCWE-injected mice (Burns, 2012; Lee et al.,
2012). A recent case report showed a dramatic effect on rescuing
a life-threatening case of relapsing KD (Cohen et al., 2012).
Genetics: IL-1 Pathway and Calcium
Signaling
Finally, analysis of the whole-genome expression profile of acute
KD patients has pointed out the importance of IL-1β activation
in KD inflammatory profile by showing the link between calcium
concentration and inflammasome.
Inositol-triphosphate 3-kinase C (ITPKC) is a candidate
gene located on chromosome 19q13.2 whose CC genotype
is implicated as a determinant of both disease susceptibility
and outcome in KD. ITPKC phosphorylates inositol 1, 4, 5-
triphosphate (IP3) to inositol 1, 3, 4, 5-tetraphosphate (IP4),
therefore, regulating the calcium response to extracellular signals.
At the same time, NLRP3 inflammasome has been shown to
be dependent of both extracellular and intracellular calcium
concentration ([Ca2+]i). Amazingly, ITPKC CC genotype is
associated with both highest basal and stimulated [Ca2+]i
levels and increased amounts of NLRP3 protein compared with
other genotypes at baseline. These findings, allowed making
the hypothesis of a link between the calcium level and the
activation of NLRP3 in ITPKC CC genotype leading to an excess
of IL-1 secretion as in SAID. Moreover, ITPKC CC genotype is
associated with failure of IVIG therapy (Alphonse et al., 2016).
This emphasizes the fact that phenotypic similarities between TA
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KD and AID are anchored by the common immunobiological
processes associated with inflammasome activation.
Experience of IL-1 Blockade in KD
Patients
Nowadays, three IL-1 blockades have been approved: anakinra,
rilonacept, and canakinumab. Anakinra (Kineret R©) was the
first IL-1 blockade agent administered initially in rheumatoid
arthritis (1993) and is now used in numerous diseases such
as hereditary SAIDs (Schett et al., 2016). It is an IL1-RA
blocking both IL-1α and IL-1β (Carter et al., 1990). In 2008,
rilonacept (Hoffman et al., 2008), a soluble IL-1 decoy receptor,
that neutralizes either IL-1α or IL-1β, received US Food and
Drug Administration (FDA) approval in CAPS patients, and
Canakinumab (Ilaris R©) in 2009 (Chakraborty et al., 2012). The
latter is a humanized monoclonal antibody that specifically
blocks IL-1β (Dinarello et al., 2012). In pediatrics, only anakinra
(≥8 months and 10 kg) and canakinumab (≥24 months and
≥7.5 kg) have FDA and European Medicines Agency (EMA)
approval for CAPS disease. These IL-1 blockades are safe and
well tolerated with a low-adverse event rate (Rossi-Semerano
et al., 2015). Anakinra is preferred for it has a remarkable
record of safety with over 150,000 patients treated daily for over
10 years (Bresnihan et al., 2004; Fleischmann et al., 2006). In
addition, drug level significantly drops 1 h after discontinuation
of treatment (Dinarello et al., 2012).
In SJIA, the three IL-1 blockers have been tested so far and
were proven as effective and safe, although only canakinumab is
currently approved for use (Giancane et al., 2016). In addition,
anakinra has been demonstrated as efficient in severe SJIA with
MAS (Miettunen et al., 2011) a severe complication that can
occur in up to half of SJIA patients. In KD, MAS is probably a
frequently under-recognized complication situation which could
benefit from IL-1 blockers (Wang et al., 2015).
For now, two case reports showing promising results with
anakinra in severe KD patient have been published. The first
one is an 11-week-old Caucasian female that presented with
severe KD complicated by MAS. Diffuse enlargement of the
entire coronary artery system was revealed by echocardiogram.
IVIG, aspirin and CS were inefficient. High doses of anakinra
(3 mg/kg/dose, twice daily for 3 days) were introduced at day
6 because of bad clinical outcome and biological signs of MAS.
IFX and methylprednisolone were added at day 9 because of
cardiac failure despite favorable clinical and biological course.
The evolution was favorable allowing CS to be tapered off
over 10 days following discharge and under anakinra over the
next 5 months. At 8 months, the echocardiogram was normal
(Shafferman et al., 2014).
The second one is a 2-year-old boy diagnosed with KD
who developed secondarily cardiac failure (shortening fraction
of 20%) without CAA under IVIG (2 g/kg) treatment.
A second IVIG perfusion was administered as well as multiple
methylprednisolone pulses with little effect and worsening of
cardiac involvement. Extracorporeal membrane oxygenation was
performed from day 14 until day 17 and subcutaneous anakinra
(1 mg/kg/day) was introduced at day 18 until day 24 with success.
Relapse was seen three days after anakinra’s last injection with
progression to giant CAA. Anakinra was therefore reinitiated for
6 weeks with normalization of the coronary lesions at 6 months
(Cohen et al., 2012).
What Could Be the Place of Anti-IL1 in
the Current Standard of KD Treatments?
Considering current knowledge, it seems reasonable to use IL-1
blockade in resistant KD with CAA before IFX which has not
proven its efficiency in coronary disease. A new approach could
be the early use of IL-1 blockade associated with CS in patients
at high risks of severe KD depending on validated risk scores,
in Japanese patients. Apart from IVIG’s, anti-IL1 are the only
therapies that have proven their effect on CAA. It should be
considered whether their use should not be generalized to all
patients. Indeed, IL-1 blockers seem to better prevent CAA
development than IVIG, especially if used at diagnosis. In this
idea three clinical trials of IL-1 blockade enrolling KD patients
are currently being conducted in Western Europe and in the US
(Table 2) (Burns et al., 2016). Their conclusion may help to better
define, in the future, the place of IL-1 blockade in KD treatment
in association or in replacement of IGIV and CS.
CONCLUSION
Kawasaki disease clinical and immunological features mimic
SAID. These similarities have allowed looking at new
inflammatory cytokines such as IL-1. Better understanding of
IL-1 involvement in KD and specifically in CAA with the use of
IL-1 blockers, has brought hope for resistant and severe patients.
Doses and time to introduce IL-1 therapy has still to be defined.
Another challenge is the need to better define patients with a
higher risk of CAA, allowing better medical care and the use of
new treatment strategies. We hope that results of clinical trials
using IL-1 blockade will allow to better understand the respective
roles of IL-1α and β, and to pursue with phase III trials.
AUTHOR CONTRIBUTIONS
Both the authors had a substantial contribution to the work. PD
wrote the first draft. PD and IK-P were involved in drafting the
article or critically revising it for important intellectual content
and approved the final version to be published.
REFERENCES
Alphonse, M. P., Duong, T. T., Shumitzu, C., Hoang, T. L., McCrindle,
B. W., Franco, A., et al. (2016). Inositol-triphosphate 3-kinase C mediates
inflammasome activation and treatment response in kawasaki disease.
J. Immunol. 197, 3481–3489. doi: 10.4049/jimmunol.1600388
Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A. I., Martínez, C. M., Amores-
Iniesta, J., Compan, V., et al. (2014). The NLRP3 inflammasome is released
Frontiers in Pharmacology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 163
fphar-08-00163 March 24, 2017 Time: 18:41 # 6
Dusser and Koné-Paut IL-1 Inhibition and Kawasaki Disease
as a particulate danger signal that amplifies the inflammatory response. Nat.
Immunol. 15, 738–748. doi: 10.1038/ni.2919
Bresnihan, B., Newmark, R., Robbins, S., and Genant, H. K. (2004). Effects of
anakinra monotherapy on joint damage in patients with rheumatoid arthritis.
Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol. 31,
1103–1111.
Brown, T. J., Crawford, S. E., Cornwall, M. L., Garcia, F., Shulman, S. T., and
Rowley, A. H. (2001). CD8 T lymphocytes and macrophages infiltrate coronary
artery aneurysms in acute Kawasaki disease. J. Infect. Dis. 184, 940–943.
doi: 10.1086/323155
Burns, J. C. (2012). Of mice and children: lessons from a Kawasaki mouse model.
Circulation 125, 1480–1481. doi: 10.1161/CIRCULATIONAHA.112.093930
Burns, J. C., Best, B. M., Mejias, A., Mahony, L., Fixler, D. E., Jafri, H. S.,
et al. (2008). Infliximab treatment of intravenous immunoglobulin-resistant
Kawasaki disease. J. Pediatr. 153, 833–838. doi: 10.1016/j.jpeds.2008.06.011
Burns, J. C., and Glodé, M. P. (2004). Kawasaki syndrome. Lancet Lond. Engl. 364,
533–544. doi: 10.1016/S0140-6736(04)16814-1
Burns, J. C., Koné-Paut, I., Kuijpers, T., Shimizu, C., Tremoulet, A., and Arditi, M.
(2016). Found in Translation: international initiatives pursuing interleukin-
1 blockade for treatment of acute Kawasaki Disease. Arthritis Rheumatol. 69,
268–276. doi: 10.1002/art.39975
Burns, J. C., Mason, W. H., Hauger, S. B., Janai, H., Bastian, J. F., Wohrley, J. D.,
et al. (2005). Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr.
146, 662–667. doi: 10.1016/j.jpeds.2004.12.022
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C. S., Laborde, A. L.,
Slightom, J. L., et al. (1990). Purification, cloning, expression and biological
characterization of an interleukin-1 receptor antagonist protein. Nature 344,
633–638. doi: 10.1038/344633a0
Chakraborty, A., Tannenbaum, S., Rordorf, C., Lowe, P. J., Floch, D.,
Gram, H., et al. (2012). Pharmacokinetic and pharmacodynamic properties
of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin.
Pharmacokinet. 51, e1–e18. doi: 10.2165/11599820-000000000-00000
Chen, S., Dong, Y., Yin, Y., and Krucoff, M. W. (2013). Intravenous
immunoglobulin plus corticosteroid to prevent coronary artery abnormalities
in Kawasaki disease: a meta-analysis. Heart 99, 76–82. doi: 10.1136/heartjnl-
2012-302126
Cohen, S., Tacke, C. E., Straver, B., Meijer, N., Kuipers, I. M., and Kuijpers, T. W.
(2012). A child with severe relapsing Kawasaki disease rescued by IL-1 receptor
blockade and extracorporeal membrane oxygenation. Ann. Rheum. Dis. 71,
2059–2061. doi: 10.1136/annrheumdis-2012-201658
Dinarello, C. A., Simon, A., and van der Meer, J. W. M. (2012). Treating
inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat.
Rev. Drug Discov. 11, 633–652. doi: 10.1038/nrd3800
Eleftheriou, D., Levin, M., Shingadia, D., Tulloh, R., Klein, N. J., and Brogan,
P. A. (2014). Management of Kawasaki disease. Arch. Dis. Child. 99, 74–83.
doi: 10.1136/archdischild-2012-302841
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R.,
Bennett, R., et al. (2006). Safety of extended treatment with anakinra in patients
with rheumatoid arthritis. Ann. Rheum. Dis. 65, 1006–1012. doi: 10.1136/ard.
2005.048371
Fury, W., Tremoulet, A. H., Watson, V. E., Best, B. M., Shimizu, C., Hamilton, J.,
et al. (2010). Transcript abundance patterns in Kawasaki disease patients
with intravenous immunoglobulin resistance. Hum. Immunol. 71, 865–873.
doi: 10.1016/j.humimm.2010.06.008
Galeotti, C., Bayry, J., Kone-Paut, I., and Kaveri, S. V. (2010). Kawasaki disease:
aetiopathogenesis and therapeutic utility of intravenous immunoglobulin.
Autoimmun. Rev. 9, 441–448. doi: 10.1016/j.autrev.2009.12.004
Galeotti, C., Kaveri, S. V., Cimaz, R., Koné-Paut, I., and Bayry, J. (2016).
Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki
disease. Drug Discov. Today 21, 1850–1857. doi: 10.1016/j.drudis.2016.
08.004
Giancane, G., Minoia, F., Davì, S., Bracciolini, G., Consolaro, A., and Ravelli, A.
(2016). IL-1 inhibition in systemic juvenile idiopathic arthritis. Front.
Pharmacol. 7:467. doi: 10.3389/fphar.2016.00467
Goldbach-Mansky, R. (2012). Immunology in clinic review series; focus on
autoinflammatory diseases: update on monogenic autoinflammatory diseases:
the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.
Clin. Exp. Immunol. 167, 391–404. doi: 10.1111/j.1365-2249.2011.04533.x
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A.,
et al. (2008). Efficacy and safety of rilonacept (interleukin-1 Trap) in patients
with cryopyrin-associated periodic syndromes: results from two sequential
placebo-controlled studies. Arthritis Rheum. 58, 2443–2452. doi: 10.1002/art.
23687
Kawasaki, T. (1967). [Acute febrile mucocutaneous syndrome with lymphoid
involvement with specific desquamation of the fingers and toes in children].
Arerugi 16, 178–222.
Koné-Paut, I., and Galeotti, C. (2015). Current treatment recommendations and
considerations for cryopyrin-associated periodic syndrome. Expert Rev. Clin.
Immunol. 11, 1083–1092. doi: 10.1586/1744666X.2015.1077702
Lee, Y., Schulte, D. J., Shimada, K., Chen, S., Crother, T. R., Chiba, N., et al. (2012).
Interleukin-1β is crucial for the induction of coronary artery inflammation in
a mouse model of Kawasaki disease. Circulation 125, 1542–1550. doi: 10.1161/
CIRCULATIONAHA.111.072769
Lefèvre-Utile, A., Galeotti, C., and Koné-Paut, I. (2014). Coronary artery
abnormalities in children with systemic-onset juvenile idiopathic arthritis. Joint
Bone Spine 81, 257–259. doi: 10.1016/j.jbspin.2013.09.004
Lehman, T. J. (1993). Can we prevent long term cardiac damage in Kawasaki
disease? Lessons from Lactobacillus casei cell wall-induced arteritis in mice.
Clin. Exp. Rheumatol. 11(Suppl. 9), S3–S6.
Lehman, T. J., Walker, S. M., Mahnovski, V., and McCurdy, D. (1985). Coronary
arteritis in mice following the systemic injection of group B Lactobacillus casei
cell walls in aqueous suspension. Arthritis Rheum. 28, 652–659.
Martinon, F., and Tschopp, J. (2004). Inflammatory caspases: linking an
intracellular innate immune system to autoinflammatory diseases. Cell 117,
561–574. doi: 10.1016/j.cell.2004.05.004
Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., and Cron,
R. Q. (2011). Successful treatment of severe paediatric rheumatic disease-
associated macrophage activation syndrome with interleukin-1 inhibition
following conventional immunosuppressive therapy: case series with 12
patients. Rheumatol. Oxf. Engl. 50, 417–419. doi: 10.1093/rheumatology/keq218
Miura, M., Kohno, K., Ohki, H., Yoshiba, S., Sugaya, A., and Satoh, M. (2008).
Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease
patients unresponsive to intravenous immunoglobulin. Eur. J. Pediatr. 167,
1119–1123. doi: 10.1007/s00431-007-0642-5
Mizuta, M., Shimizu, M., Inoue, N., Kasai, K., Nakagishi, Y., Takahara, T., et al.
(2016). Serum ferritin levels as a useful diagnostic marker for the distinction
of systemic juvenile idiopathic arthritis and Kawasaki disease. Mod. Rheumatol.
doi: 10.3109/14397595.2016.1159120 [Epub ahead of print].
Newburger, J. W., Takahashi, M., Gerber, M. A., Gewitz, M. H., Tani, L. Y.,
Burns, J. C., et al. (2004). Diagnosis, treatment, and long-term management of
Kawasaki disease: a statement for health professionals from the committee on
rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular
disease in the young, american heart association. Pediatrics 114, 1708–1733.
doi: 10.1542/peds.2004-2182
Ogata, S., Bando, Y., Kimura, S., Ando, H., Nakahata, Y., Ogihara, Y., et al. (2009).
The strategy of immune globulin resistant Kawasaki disease: a comparative
study of additional immune globulin and steroid pulse therapy. J. Cardiol. 53,
15–19. doi: 10.1016/j.jjcc.2008.08.002
Pascual, V., Allantaz, F., Arce, E., Punaro, M., and Banchereau, J. (2005). Role of
interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic
arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479–1486.
doi: 10.1084/jem.20050473
Rosenkranz, M. E., Schulte, D. J., Agle, L. M. A., Wong, M. H., Zhang, W.,
Ivashkiv, L., et al. (2005). TLR2 and MyD88 contribute to Lactobacillus casei
extract-induced focal coronary arteritis in a mouse model of Kawasaki disease.
Circulation 112, 2966–2973. doi: 10.1161/CIRCULATIONAHA.105.537530
Rossi-Semerano, L., Fautrel, B., and Wendling, D. (2015). Tolerance and efficacy of
off-label anti-interleukin-1 treatments in France: a nationwide survey.Orphanet
J. Rare Dis. 10, 19. doi: 10.1186/s13023-015-0228-7
Schett, G., Dayer, J.-M., and Manger, B. (2016). Interleukin-1 function and role
in rheumatic disease. Nat. Rev. Rheumatol. 12, 14–24. doi: 10.1038/nrrheum.
2016.166
Schulte, D. J., Yilmaz, A., Shimada, K., Fishbein, M. C., Lowe, E. L., Chen, S., et al.
(2009). Involvement of innate and adaptive immunity in a murine model of
coronary arteritis mimicking Kawasaki disease. J. Immunol. 183, 5311–5318.
doi: 10.4049/jimmunol.0901395
Frontiers in Pharmacology | www.frontiersin.org 6 March 2017 | Volume 8 | Article 163
fphar-08-00163 March 24, 2017 Time: 18:41 # 7
Dusser and Koné-Paut IL-1 Inhibition and Kawasaki Disease
Shafferman, A., Birmingham, J. D., and Cron, R. Q. (2014). High dose Anakinra
for treatment of severe neonatal Kawasaki disease: a case report. Pediatr.
Rheumatol. Online J. 12:26. doi: 10.1186/1546-0096-12-26
Son, M. B., Gauvreau, K., Burns, J. C., Corinaldesi, E., Tremoulet, A. H.,
Watson, V. E., et al. (2011). Infliximab for intravenous immunoglobulin
resistance in Kawasaki disease: a retrospective study. J. Pediatr. 158, 644–649.e1.
doi: 10.1016/j.jpeds.2010.10.012
Ter Haar, N., Lachmann, H., Özen, S., Woo, P., Uziel, Y., Modesto, C., et al. (2013).
Treatment of autoinflammatory diseases: results from the eurofever registry and
a literature review. Ann. Rheum. Dis. 72, 678–685. doi: 10.1136/annrheumdis-
2011-201268
Wang, W., Gong, F., Zhu, W., Fu, S., and Zhang, Q. (2015). Macrophage activation
syndrome in Kawasaki disease: more common than we thought? Semin.
Arthritis Rheum. 44, 405–410. doi: 10.1016/j.semarthrit.2014.07.007
Weng, K.-P., Ho, T.-Y., Chiao, Y.-H., Cheng, J.-T., Hsieh, K.-S., Huang, S.-H., et al.
(2010). Cytokine genetic polymorphisms and susceptibility to Kawasaki disease
in Taiwanese children. Circ. J. 74, 2726–2733.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Dusser and Koné-Paut. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 7 March 2017 | Volume 8 | Article 163
